In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

In early June 2026, ADC Therapeutics reported topline Phase 3 LOTIS-5 data showing ZYNLONTA plus rituximab improved progression-free survival and response depth versus R-GemOx in relapsed or ...

Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.

ADC Therapeutics SA ADCT stock is trading lower on Thursday after the company indicated that LOTIS-5 showed elevated serious ...

ADC Therapeutics ADCT shares plunged 53.4% in after-hours trading on Wednesday despite the company reporting positive ...

The addition of two agents to standard first-line treatment significantly improved PFS among patients with aggressive B-cell lymphomas, according to results of the randomized phase 3 frontMIND ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Paolo F. Caimi, MD, MBA, staff physician at Cleveland Clinic, discusses the phase 2/3 ...

MicroRNAs are small non-coding RNAs, typically 20–24 nucleotides long, that modulate gene expression post-transcriptionally by binding to complementary sequences in target messenger RNAs. In B-cell ...

B-cell lymphoma is a type of non-Hodgkin lymphoma. It’s also the most common type of lymphoma. Approximately 85% of all lymphomas in the United States are B-cell lymphomas. Non-Hodgkin lymphomas are ...